2 days Ago By Defense World Staff
Commonwealth Equity Services LLC bought a new position in shares of Compugen Ltd. ( NASDAQ:CGEN – Free Report ) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 20,791 shares of the biotechnology company’s stock, valued at approximately $32,000.
A number of other hedge funds also recently modified their holdings of CGEN. Connor Clark & Lunn Investment Management Ltd. grew its stake in Compugen by 15.
7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 317,500 shares of the biotechnology company’s stock worth $486,000 after buying an additional 43,165 shares in the last quarter.
Raymond James Financial Inc. acquired a new position in shares of Compugen in the 4th quarter valued at approximately $103,000. Finally, Oppenheimer & Co.
Inc. lifted its holdings in shares of Compugen by 187.3% during the 4th quarter.
Oppenheimer & Co. Inc. now owns 55,602 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 36,252 shares during the period.
Institutional investors own 12.22% of the company’s stock. Analyst Ratings Changes CGEN has been the topic of a number of recent analyst reports.
Oppenheimer began coverage on shares of Compugen in a research note on Monday, January 13th. They issued an “outperform” rating and a $4.00 price objective on the stock.
StockNews.com downgraded Compugen from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th. Compugen Trading Up 4.
1 % Shares of NASDAQ CGEN opened at $1.26 on Friday. The stock has a 50-day moving average price of $1.
76 and a two-hundred day moving average price of $1.75. Compugen Ltd.
has a 12 month low of $1.13 and a 12 month high of $2.66.
The company has a market cap of $112.44 million, a price-to-earnings ratio of 63.00 and a beta of 3.
19. Compugen ( NASDAQ:CGEN – Get Free Report ) last released its quarterly earnings data on Tuesday, March 4th. The biotechnology company reported ($0.
07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.14).
Compugen had a return on equity of 2.62% and a net margin of 2.67%.
The company had revenue of $1.47 million for the quarter, compared to analyst estimates of $17.47 million.
On average, sell-side analysts predict that Compugen Ltd. will post -0.03 earnings per share for the current year.
Compugen Company Profile ( Free Report ) Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.
Featured Articles Five stocks we like better than Compugen What is the MACD Indicator and How to Use it in Your Trading JPMorgan is a Buy, if You Can Handle The Volatility 3 Dividend Kings To Consider United States Steel’s Crash: An Unmissable Buying Opportunity How to Plot Fibonacci Price Inflection Levels Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter ..
